Rene Hurlemann, MD, PhD, MBA

  • Professor of Psychiatry and Psychotherapy

  • Head of the Department of Psychiatry and Psychotherapy at the University of Oldenburg

  • Head of the Neuromodulation of Emotion (NEMO) Lab

  • Associate Dean for Strategic Development

  • Chief Medical Officer (CMO) of Karl Jaspers Clinic

Hurlemann 1.jpg

Rene Hurlemann is Professor of Psychiatry and Psychotherapy and Head of the Department of Psychiatry and Psychotherapy at the University of Oldenburg, Germany. The department is part of the Karl Jaspers Clinic in Wehnen near Oldenburg, the second largest maximum care psychiatric hospital in Lower Saxony. Rene Hurlemann serves the Karl Jaspers Clinic as Chief Medical Officer (CMO) and the School of Medicine and Life Sciences of the University of Oldenburg as Associate Dean for Strategic Development. Rene Hurlemann holds a PhD from Maastricht University, an MD from the University of Bonn and an MBA from Frankfurt School of Finance & Management. As a clinical scientist, his focus is on the advancement of personalized medicine, which is thought to play a key role in overcoming treatment resistance. Rene Hurlemann leads an interdisciplinary research team that investigates the social (e.g. loneliness) and environmental (e.g. climate change) determinants of mental health and translates the findings into innovative clinical treatments, including non-invasive neuromodulation with accelerated theta burst stimulation (TBS) and AI-based digital aftercare. His research is funded by various sources, including the German Research Foundation (DFG), the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Climate Policy (BMWK). Rene Hurlemann is a research associate at the Laureate Institute for Brain Research (LIBR), Tulsa (OK, USA), and co-director of the Summer School on Affective Neuroscience, coordinated by Maastricht University. He is a member of more than ten professional societies, including the American College of Neuropsychopharmacology (ACNP) and the Society of Biological Psychiatry (SoBP). Furthermore, he is a member of several editorial boards of scientific journals, including Personalized Medicine in Psychiatry (Elsevier), Social Cognitive & Affective Neuroscience (SCAN) (Oxford Academic) and Journal of Psychiatric Research (Elsevier). Moreover, he is an international ad hoc referee for numerous journals and funding organizations as well as academic appointment and award committees in the fields of psychiatry and neuroscience.

Related links:

Recommended Reading:

  • Hurlemann R & Domschke K (2024) Challenging treatment resistance. Nervenarzt 95: 405 - 406 (article in German) PDF

  • Baune BT, Fromme SE, Kiebs M, Hurlemann R (2024) Clinical management of treatment-resistant depression. Nervenarzt 95: 416 - 422 (article in German) PDF

  • Rethinking mental healthcare: harnessing new approaches (2024) The Economist Impact PDF

Abbreviations: IF, Journal Impact Factor